Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,210
Out of 4,876 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $41.73 | +0.65% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $188.52 | +98.92% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $71.14 | +61.65% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $87.81 | +4.77% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $15.15 | -20.79% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $10.74 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $40.93 | +119.89% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $238.79 | +13.07% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $101.42 | -32.95% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $12.21 | +268.55% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $119.47 | +130.18% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $16.92 | +118.68% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $86.33 | -30.50% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $106.53 | -67.15% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $313.08 | -74.13% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $41.73
Upside: +0.65%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $188.52
Upside: +98.92%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $71.14
Upside: +61.65%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $87.81
Upside: +4.77%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $15.15
Upside: -20.79%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $10.74
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $40.93
Upside: +119.89%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $238.79
Upside: +13.07%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $101.42
Upside: -32.95%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $12.21
Upside: +268.55%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $119.47
Upside: +130.18%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $16.92
Upside: +118.68%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $86.33
Upside: -30.50%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $106.53
Upside: -67.15%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $313.08
Upside: -74.13%